ATE485296T1 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit - Google Patents

(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Info

Publication number
ATE485296T1
ATE485296T1 AT04752844T AT04752844T ATE485296T1 AT E485296 T1 ATE485296 T1 AT E485296T1 AT 04752844 T AT04752844 T AT 04752844T AT 04752844 T AT04752844 T AT 04752844T AT E485296 T1 ATE485296 T1 AT E485296T1
Authority
AT
Austria
Prior art keywords
pyridinyl
dichloro
analgesic effectiveness
analgesic
effectiveness
Prior art date
Application number
AT04752844T
Other languages
English (en)
Inventor
Michael Buckley
Jianguo Ji
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE485296T1 publication Critical patent/ATE485296T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04752844T 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit ATE485296T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
ATE485296T1 true ATE485296T1 (de) 2010-11-15

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752844T ATE485296T1 (de) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Country Status (22)

Country Link
US (1) US20040242641A1 (de)
EP (1) EP1626973B1 (de)
JP (1) JP4716999B2 (de)
KR (2) KR20060015738A (de)
CN (1) CN1826344B (de)
AT (1) ATE485296T1 (de)
AU (1) AU2004243270B2 (de)
BR (1) BRPI0410808A (de)
CA (1) CA2526530C (de)
CY (1) CY1111946T1 (de)
DE (1) DE602004029671D1 (de)
DK (1) DK1626973T3 (de)
ES (1) ES2352199T3 (de)
HK (1) HK1092135A1 (de)
MX (1) MXPA05012738A (de)
NZ (2) NZ588123A (de)
PL (1) PL1626973T3 (de)
PT (1) PT1626973E (de)
SI (1) SI1626973T1 (de)
TW (1) TWI332502B (de)
WO (1) WO2004106342A1 (de)
ZA (1) ZA200509601B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
EP2491034B1 (de) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Kondensierte heterocyclische verbindungen als orexinrezeptormodulatoren
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
KR20120105449A (ko) 2009-10-23 2012-09-25 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
TW201129361A (en) * 2010-01-20 2011-09-01 Abbott Lab Methods for treating pain
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
BR0007664A (pt) * 1999-01-29 2002-05-07 Abbott Lab Derivados diazabicìclicos como ligantes receptores de acetilcolina nicotìnicos
AU773830B2 (en) * 1999-04-26 2004-06-10 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
PT1178982E (pt) * 1999-05-21 2004-11-30 Abbott Lab Aminoazaciclos heterociclicos substituidos uteis como agentes do sistema nervosocentral
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
KR20060015738A (ko) 2006-02-20
HK1092135A1 (en) 2007-02-02
CA2526530C (en) 2013-01-08
AU2004243270B2 (en) 2009-12-17
PT1626973E (pt) 2010-12-31
TWI332502B (en) 2010-11-01
JP2007500220A (ja) 2007-01-11
PL1626973T3 (pl) 2011-04-29
JP4716999B2 (ja) 2011-07-06
MXPA05012738A (es) 2006-02-22
DE602004029671D1 (de) 2010-12-02
CN1826344B (zh) 2013-03-06
CY1111946T1 (el) 2015-11-04
CN1826344A (zh) 2006-08-30
DK1626973T3 (da) 2011-01-10
BRPI0410808A (pt) 2006-06-27
SI1626973T1 (sl) 2011-01-31
KR20120014235A (ko) 2012-02-16
ZA200509601B (en) 2006-10-25
NZ543615A (en) 2009-04-30
KR101238281B1 (ko) 2013-03-04
NZ588123A (en) 2012-04-27
AU2004243270A1 (en) 2004-12-09
US20040242641A1 (en) 2004-12-02
EP1626973A1 (de) 2006-02-22
EP1626973B1 (de) 2010-10-20
WO2004106342A1 (en) 2004-12-09
CA2526530A1 (en) 2004-12-09
ES2352199T3 (es) 2011-02-16
TW200510420A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MXPA02012681A (es) Compuestos de sales de ditosilato de quinazolina.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2005107726A3 (en) Method for the treatment of back pain
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2002066500A3 (de) ANTAGONISTEN FÜR Α4β7-INTEGRIN
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
SE9802208D0 (sv) Novel compounds
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
SE9802209D0 (sv) Novel compounds
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ITMI20030972A1 (it) Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1626973

Country of ref document: EP